The Association Between Different Markers With Development of Maternal and Neonatal Complications in Women With Severe Preeclampsia
NCT ID: NCT07125599
Last Updated: 2025-08-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
284 participants
OBSERVATIONAL
2020-05-02
2025-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Complete physical examination: general (including BMI \& blood pressure measurement) and obstetric examinations.
* Routine obstetric ultrasound and Doppler indices Including umbilical artery Doppler (RI).
* Laboratory investigations :
1\. Complete blood count (CBC). 2 albuminuria will be detected by dipstick kits . 3. Liver enzymes \& kidney function. 4.PT,PC,INR.
* Pelvic-Abdominal ultrasound to assess the presence of ascites Ultrasound examination will be performed by a consultant obstetrician to detect free fluid in the peritoneal cavity, especially at hepato-renal pouch, sub-splenic area, or para-colic gutters.
The presence of ascites will be further confirmed at the time of delivery.
3-All labours will be attended by an expert neonatologist and the following will be recorded:
* APGAR score at (1 min).
* The further need for neonatal intensive care unit (NICU) admission.
* Perinatal death
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serpin C and Soluble Fms-like Tyrosine Kinase-1 Levels in Normotensive Pregnant Women May Predict the Development of Preeclampsia
NCT06214702
Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia
NCT02350036
Maternal and Neonatal Outcome in Severe Preeclampsia
NCT04126122
Improved Characterisation of Eclampsia
NCT05199558
Vascular Endothelial Factor Gene Polymorphism in Preeclampsia
NCT03500588
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Complete physical examination: general (including BMI \& blood pressure measurement) and obstetric examinations.
* Routine obstetric ultrasound and Doppler indices Including umbilical artery Doppler (RI).
* Laboratory investigations :
1\. Complete blood count (CBC). 2 albuminuria will be detected by dipstick kits . 3. Liver enzymes \& kidney function. 4.PT,PC,INR.
* Pelvic-Abdominal ultrasound to assess the presence of ascites Ultrasound examination will be performed by a consultant obstetrician to detect free fluid in the peritoneal cavity, especially at hepato-renal pouch, sub-splenic area, or para-colic gutters.
The presence of ascites will be further confirmed at the time of delivery.
3-All labours will be attended by an expert neonatologist and the following will be recorded:
* APGAR score at (1 min).
* The further need for neonatal intensive care unit (NICU) admission.
* Perinatal death
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Gestational age (28\_38) weeks, confirmed by the first day of the last menstrual period or first trimesteric ultrasound
3. All suffering of severe preeclampsia
Exclusion Criteria
2. Maternal medical disorders rather than hypertension.
3. Rupture of membrane.
4. Renal disorder.
5. History of illicit drug use.
6. Fetal congenital anomalies.
7. The maternal administration of respiratory depressants within 2 hours from the delivery of the fetus (e. g., opioid analgesic )
8. Associated inflammatory disease or sepsis.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed M Maged, MD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed Maged, MD
Role: PRINCIPAL_INVESTIGATOR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cairo university
Cairo, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cairo university
Identifier Type: OTHER
Identifier Source: secondary_id
366
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.